Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas
Martin P FR, Rutherford S, Ruan J, Ely S, Greenberg J, Coleman M, Goldenberg DM, Wegener WA, Sharkey RM, Goldsmith SJ, Leonard JP, Leukemia and Lymphoma, 1/1/2015Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kian..., Ann Oncol, 1/1/2008"High-grade MALT" vs diffuse large B cell lymphoma
Ely, SA, Gastroenterology, 1/1/2002
